Table 4.
Concomitant psychotropic treatment, co-prescribed agents and CGI-I outcome by treatment type.
| Variable | All patients, n (%) N = 650 | Concomitant treatment, n (%) n = 285 |
|---|---|---|
| Concomitant treatment (clinician-coded) | ||
| No (antidepressant monotherapy) | 365 (56.2) | – |
| Yes | 285 (43.8) | – |
| Reason for concomitant treatment, n = 285 | ||
| Comorbid psychiatric condition | – | 158 (55.4) |
| Partial response (augmentation) | – | 125 (43.9) |
| Not specified | – | 2 (0.7) |
| Co-prescribed psychotropic agents recorded | ||
| Any co-prescribed psychotropic agent | 349 (53.7) | 266 (93.3) |
| Antipsychotics | 236 (36.3) | 229 (80.4) |
| Risperidone | 114 (17.5) | 109 (38.2) |
| Aripiprazole | 61 (9.4) | 59 (20.7) |
| Quetiapine | 29 (4.5) | 29 (10.2) |
| Haloperidol | 19 (2.9) | 19 (6.7) |
| Olanzapine | 15 (2.3) | 15 (5.3) |
| Zuclopenthixol | 1 (0.2) | 1 (0.4) |
| Chlorpromazine | 1 (0.2) | 1 (0.4) |
| ADHD medications | 147 (22.6) | 67 (23.5) |
| OROS methylphenidate | 64 (9.8) | 33 (11.6) |
| Immediate-release methylphenidate | 34 (5.2) | 6 (2.1) |
| Atomoxetine | 49 (7.5) | 28 (9.8) |
| Mood stabilisers | 17 (2.6) | 17 (6.0) |
| Sodium valproate | 11 (1.7) | 11 (3.9) |
| Lithium | 4 (0.6) | 4 (1.4) |
| Carbamazepine | 2 (0.3) | 2 (0.7) |
| Benzodiazepines | 15 (2.3) | 15 (5.3) |
| Alprazolam | 8 (1.2) | 8 (2.8) |
| Clonazepam | 5 (0.8) | 5 (1.8) |
| Lorazepam | 1 (0.2) | 1 (0.4) |
| Diazepam | 1 (0.2) | 1 (0.4) |
| Other agents | 24 (3.7) | 24 (8.4) |
| Propranolol | 24 (3.7) | 24 (8.4) |
| Hydroxyzine | 1 (0.2) | 1 (0.4) |
| CGI-I at last recorded follow-up | ||
| Positive response (1–2), monotherapy, n = 365 | 363 (99.5) | – |
| Positive response (1–2), concomitant treatment, n = 285 | – | 187 (65.6) |
Concomitant treatment was coded by the treating clinician as the addition of another psychotropic agent because of a comorbid psychiatric condition or partial response. Co-prescribed agents are those recorded in the medical record at the time of antidepressant treatment; some patients coded as receiving monotherapy had an ADHD medication (or, rarely, an antipsychotic) recorded, and some patients received more than one co-prescribed agent. CGI-I, Clinical Global Impression–Improvement; OROS, osmotic-release oral system.